Detalhe da pesquisa
1.
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
N Engl J Med
; 388(23): 2159-2170, 2023 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36972022
2.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898292
3.
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 159(1): 79-87, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723679
4.
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
Int J Gynecol Cancer
; 30(5): 596-601, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32114513
5.
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 152(3): 548-553, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587441
6.
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Gynecol Oncol
; 155(3): 420-428, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31623857
7.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Lancet
; 390(10103): 1654-1663, 2017 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28756902
8.
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 151(2): 257-263, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30177462
9.
Improved survival with bevacizumab in advanced cervical cancer.
N Engl J Med
; 370(8): 734-43, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24552320
10.
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 146(3): 477-483, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28756871
11.
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(2): 291-297, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285845
12.
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Gynecol Oncol
; 144(1): 96-100, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094040
13.
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 138(1): 36-40, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25958319
14.
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 138(1): 30-5, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25887099
15.
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Gynecol Oncol
; 138(3): 513-8, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26171911
16.
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 138(3): 507-12, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26186911
17.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 137(3): 386-91, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25818403
18.
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol
; 135(3): 441-5, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25312396
19.
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
Gynecol Oncol
; 133(3): 433-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24708919
20.
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol
; 135(1): 38-43, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25019571